Mundipharma Medical Company
Quick facts
Phase 3 pipeline
- Sevre-Long™ · Diabetes
Sevre-Long™ is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to regulate glucose metabolism.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Mundipharma Medical Company
What is Mundipharma Medical Company's pipeline?
Mundipharma Medical Company has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Sevre-Long™.
Related
- Sector hub: All tracked pharma companies